Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas

Andrew D. Norden; Andrew D. Norden; David Schiff; Manmeet S. Ahluwalia; Glenn J. Lesser; Lakshmi Nayak; Lakshmi Nayak; Eudocia Q. Lee; Eudocia Q. Lee; Mikael L. Rinne; Mikael L. Rinne; Alona Muzikansky; Jorg Dietrich; Benjamin Purow; Lisa M. Doherty; Debra C. LaFrankie; Julee R. Pulverenti; Jennifer A. Rifenburg; Sandra F. Ruland; Katrina H. Smith; Sarah C. Gaffey; Christine McCluskey; Keith L. Ligon; Keith L. Ligon; David A. Reardon; Patrick Y. Wen; Patrick Y. Wen

doi:10.1007/S11060-014-1631-Y

Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas

Andrew D. Norden, Andrew D. Norden, David Schiff, Manmeet S. Ahluwalia, Glenn J. Lesser, Lakshmi Nayak, Lakshmi Nayak, Eudocia Q. Lee, Eudocia Q. Lee, Mikael L. Rinne, Mikael L. Rinne, Alona Muzikansky, Jorg Dietrich, Benjamin Purow, Lisa M. Doherty, Debra C. LaFrankie, Julee R. Pulverenti, Jennifer A. Rifenburg, Sandra F. Ruland, Katrina H. SmithSarah C. Gaffey, Christine McCluskey, Keith L. Ligon, Keith L. Ligon, David A. Reardon, Patrick Y. Wen, Patrick Y. Wen

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of neuro-oncology
Volume	121
DOIs	https://doi.org/10.1007/S11060-014-1631-Y
State	Published - Jan 1 2015

Disciplines

Medicine and Health Sciences
Oncology
Surgery
Internal Medicine

Access to Document

10.1007/S11060-014-1631-YLicense: Unspecified

Cite this

Norden, A. D., Norden, A. D., Schiff, D., Ahluwalia, M. S., Lesser, G. J., Nayak, L., Nayak, L., Lee, E. Q., Lee, E. Q., Rinne, M. L., Rinne, M. L., Muzikansky, A., Dietrich, J., Purow, B., Doherty, L. M., LaFrankie, D. C., Pulverenti, J. R., Rifenburg, J. A., Ruland, S. F., ... Wen, P. Y. (2015). Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. Journal of neuro-oncology, 121. https://doi.org/10.1007/S11060-014-1631-Y

Norden, AD, Norden, AD, Schiff, D, Ahluwalia, MS, Lesser, GJ, Nayak, L, Nayak, L, Lee, EQ, Lee, EQ, Rinne, ML, Rinne, ML, Muzikansky, A, Dietrich, J, Purow, B, Doherty, LM, LaFrankie, DC, Pulverenti, JR, Rifenburg, JA, Ruland, SF, Smith, KH, Gaffey, SC, McCluskey, C, Ligon, KL, Ligon, KL, Reardon, DA, Wen, PY & Wen, PY 2015, 'Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas', Journal of neuro-oncology, vol. 121. https://doi.org/10.1007/S11060-014-1631-Y

@article{44629b30d3b14eb19bf5da72e374cfdd,

title = "Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas",

author = "Norden, \{Andrew D.\} and Norden, \{Andrew D.\} and David Schiff and Ahluwalia, \{Manmeet S.\} and Lesser, \{Glenn J.\} and Lakshmi Nayak and Lakshmi Nayak and Lee, \{Eudocia Q.\} and Lee, \{Eudocia Q.\} and Rinne, \{Mikael L.\} and Rinne, \{Mikael L.\} and Alona Muzikansky and Jorg Dietrich and Benjamin Purow and Doherty, \{Lisa M.\} and LaFrankie, \{Debra C.\} and Pulverenti, \{Julee R.\} and Rifenburg, \{Jennifer A.\} and Ruland, \{Sandra F.\} and Smith, \{Katrina H.\} and Gaffey, \{Sarah C.\} and Christine McCluskey and Ligon, \{Keith L.\} and Ligon, \{Keith L.\} and Reardon, \{David A.\} and Wen, \{Patrick Y.\} and Wen, \{Patrick Y.\}",

note = "Bevacizumab is FDA-approved for patients with recurrent GBM. However, the median duration of response is only 4 months. Potential mechanisms of resistance include upregulated FGF signaling and increased PDGF-mediated pericyte coverage. Nintedanib is an oral, small-molecule tyrosine kinase inhibitor of PDGFR α/β, FGFR 1-3, and VEGFR 1-3 that may overcome resistance to anti-VEGF therapy.",

year = "2015",

month = jan,

day = "1",

doi = "10.1007/S11060-014-1631-Y",

language = "American English",

volume = "121",

journal = "Journal of neuro-oncology",

}

TY - JOUR

T1 - Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas

AU - Norden, Andrew D.

AU - Schiff, David

AU - Ahluwalia, Manmeet S.

AU - Lesser, Glenn J.

AU - Nayak, Lakshmi

AU - Lee, Eudocia Q.

AU - Rinne, Mikael L.

AU - Muzikansky, Alona

AU - Dietrich, Jorg

AU - Purow, Benjamin

AU - Doherty, Lisa M.

AU - LaFrankie, Debra C.

AU - Pulverenti, Julee R.

AU - Rifenburg, Jennifer A.

AU - Ruland, Sandra F.

AU - Smith, Katrina H.

AU - Gaffey, Sarah C.

AU - McCluskey, Christine

AU - Ligon, Keith L.

AU - Reardon, David A.

AU - Wen, Patrick Y.

N1 - Bevacizumab is FDA-approved for patients with recurrent GBM. However, the median duration of response is only 4 months. Potential mechanisms of resistance include upregulated FGF signaling and increased PDGF-mediated pericyte coverage. Nintedanib is an oral, small-molecule tyrosine kinase inhibitor of PDGFR α/β, FGFR 1-3, and VEGFR 1-3 that may overcome resistance to anti-VEGF therapy.

PY - 2015/1/1

Y1 - 2015/1/1

UR - https://link.springer.com/article/10.1007/s11060-014-1631-y

U2 - 10.1007/S11060-014-1631-Y

DO - 10.1007/S11060-014-1631-Y

M3 - Article

VL - 121

JO - Journal of neuro-oncology

JF - Journal of neuro-oncology

ER -

Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas

Disciplines

Access to Document

Other files and links

Cite this